Contract drug manufacturing (CDMO) stocks
CDMO
What are Contract drug manufacturing (CDMO) stocks in Korea?
The Contract drug manufacturing (CDMO) theme on jonbur groups 24 Korean stocks listed on KOSPI and KOSDAQ, worth ₩128T in total. On Oct 28, 2026 the group moved up 0.40% (weighted by market value); the largest members are Samsung Biologics, Celltrion, Hanmi Pharm.
Key facts
- Stocks
- 24
- Total market value
- ₩128T
- Day's move
- +0.40%
- As of
- Oct 28, 2026
- Largest members
- Samsung Biologics, Celltrion, Hanmi Pharm
Earnings tracker · 4Q 2025
Past quarter
Combined, for the companies that have reported, vs the same quarter a year ago
| Company | Reported | Revenue | vs a year ago | Operating profit | vs a year ago | vs last quarter | Op. margin |
|---|---|---|---|---|---|---|---|
| Samsung Biologics | Mar 12 | ₩309B | −75.4% | ₩378B | +16.1% | −48.1% | 122.5%25.9% |
| Celltrion | Mar 16 | ₩1.3T | +25.1% | ₩475B | +141.9% | +57.6% | 35.7%18.5% |
| Hanmi Pharm | Mar 20 | ₩433B | +23.1% | ₩83B | +173.4% | +51.2% | 19.2%8.7% |
| SAM Chun Dang Pharm | Mar 20 | ₩66B | +20.1% | ₩5.4B | Turned to profit | +58.0% | 8.2%−1.0% |
| SK Bioscience | Mar 13 | ₩184B | +17.4% | −₩52B | Bigger loss | Bigger loss | −28.0%−32.4% |
| ST Pharm | Mar 18 | ₩129B | +11.5% | ₩26B | +15.3% | +78.4% | 20.3%19.7% |
| GC Biopharma | Mar 18 | ₩498B | +12.9% | ₩4.6B | Turned to profit | −84.3% | 0.9%−2.3% |
| Daewoong Pharma | Mar 18 | ₩397B | +7.9% | ₩43B | +12.0% | −23.8% | 10.9%10.5% |
| Chong Kun Dang Pharmaceutical | Mar 18 | ₩427B | +2.7% | ₩23B | +247.1% | +11.9% | 5.5%1.6% |
| Proteina | Mar 20 | ₩343M | — | −₩4.4B | — | Bigger loss | −1,295.4% |
| Samyang Holdings | Mar 23 | ₩685B | −21.7% | −₩12B | Bigger loss | Turned to loss | −1.8%−0.2% |
| IL Dong Pharmaceutical | Mar 18 | ₩147B | −5.6% | ₩7.9B | −5.7% | +17.2% | 5.4%5.4% |
| Dong-A ST | Mar 18 | ₩217B | +21.4% | −₩2.7B | Smaller loss | Turned to loss | −1.3%−4.1% |
| Inventage Lab | Mar 23 | ₩1.1B | −0.6% | −₩7.5B | Bigger loss | Bigger loss | −701.4%−498.5% |
| Prestige BioPharma | Mar 3 | ₩3.9M | Turned to profit | −₩10M | Bigger loss | Bigger loss | −258.8% |
| Huons | Mar 23 | ₩165B | +12.7% | ₩9.8B | −10.8% | −0.5% | 5.9%7.5% |
| Binex | Mar 13 | ₩39B | +7.9% | −₩6.3B | Smaller loss | Turned to loss | −16.3%−19.8% |
| BNC Korea | Mar 23 | ₩24B | −8.6% | −₩2.4B | Turned to loss | Bigger loss | −10.0%6.7% |
| Kolon Life Science | Mar 18 | ₩45B | −4.6% | −₩2.7B | Smaller loss | Turned to loss | −6.0%−6.9% |
| Prestige Biologics | Feb 13 | ₩5.7B | Turned to profit | −₩4.2B | Bigger loss | Smaller loss | −73.6% |
| GL Pharm Tech | Mar 18 | ₩9.5B | +11.3% | −₩294M | Turned to loss | Turned to loss | −3.1%0.5% |
| Aprogen Biologics | Mar 20 | ₩20B | −7.6% | −₩16B | Smaller loss | Bigger loss | −78.5%−72.7% |
| SeouLin Bioscience | Mar 18 | ₩20B | +1.8% | ₩142M | Turned to profit | −81.9% | 0.7%−1.0% |
| BioInfra Life Science | Not yet | ||||||
Single-quarter figures. Preliminary figures are the company's own early numbers and are replaced by the quarterly report when it's filed. Expected dates are around when each company reported a year ago.
Technical breadth
After the close on Oct 28, 2026- Above 20-day average
- 21.7%
- Above 60-day average
- 17.4%
- RSI above 70
- 0%
- RSI below 30
- 17.4%
- 52-week highs
- 0
- 52-week lows
- 4
Index gauge · Short term
Bearish
0 bullish, 2 neutral, 7 bearish
Index gauge · Medium term
Bearish
0 bullish, 1 neutral, 7 bearish
Technical read
The contract drug manufacturing (CDMO) theme covers 23 Korean members, and only 21.7% are trading above their 20-day averages while 17.4% sit above their 60-day averages. No members are showing RSI readings in overbought territory, with the highest reading at 0, while 17.4 is the lowest RSI reading recorded, and four members have touched 52-week lows with none reaching 52-week highs. The equal-weighted member index screens bearish on both short and medium horizons, with 7 bearish signals against no bullish ones, sits below its cloud, and carries an RSI of 35.1.
Written by AI from the indicator values above. Not advice.
Share of members, from each member's own indicators; the gauge reads an equal-weighted index of the members. Technical indicators describe past price and volume patterns. They are not predictions or recommendations.
Credit & macro
- MaturitiesOct 23, 202685GC Biopharma: ₩130bn of bonds due in the next 6 months vs ₩42bn cash₩130bn due within 12 months, from the bond filings so far; cash and cash equivalents as of 2026 H1.GC Biopharma
- MaturitiesOct 20, 202685SK Reit: ₩130bn of bonds due in the next 6 months vs ₩54bn cash₩350bn due within 12 months, from the bond filings so far; cash and cash equivalents as of 2025 FY.SK ReitSK hynixSK NetworksSK DiscoverySKCSK Telecom
Creators talking about this
Contract drug manufacturing (CDMO)
+0.28%CDMO
The CDMO (contract development and manufacturing organization) theme covers Korean companies that develop and manufacture pharmaceuticals, biologics, and related products on behalf of other drug companies, rather than selling their own branded medicines. Korean investors often group these firms together because they share a business model centered on large-scale bioproduction capacity, long-term client contracts, and exposure to the global biopharma outsourcing trend. The theme is also frequently linked to the broader Korean biotech sector, so its share prices tend to move alongside related names.
24 companies · 18 up · 1 flat · 5 down
- Traded value
- ₩267B
- Value vs 20-day average
- 0.80×
- Top gainer
- Hanmi Pharm +5.42%
- Largest company
- Samsung Biologics ₩64T
Companies in this theme
| Company | Price | Daily | Traded value | Market cap | NPS |
|---|---|---|---|---|---|
Samsung Biologics207940 · KOSPI | ₩1,372,000 | −0.15% | ₩69B | ₩64T | 6.88% |
Celltrion068270 · KOSPI | ₩189,800 | +0.64% | ₩80B | ₩44T | 7.28% |
Hanmi Pharm128940 · KOSPI | ₩369,500 | +5.42% | ₩42B | ₩4.7T | 9.61% |
SAM Chun Dang Pharm000250 · KOSDAQ | ₩190,000 | +1.28% | ₩20B | ₩4.5T | 1.34% |
SK Bioscience302440 · KOSPI | ₩32,150 | +1.26% | ₩2.2B | ₩2.5T | 5.50% |
ST Pharm237690 · KOSDAQ | ₩77,200 | −3.98% | ₩29B | ₩1.6T | 5.77% |
GC Biopharma006280 · KOSPI | ₩130,500 | +1.08% | ₩1.7B | ₩1.5T | 6.68% |
Daewoong Pharma069620 · KOSPI | ₩99,900 | +0.81% | ₩2.5B | ₩1.2T | 10.30% |
Chong Kun Dang Pharmaceutical185750 · KOSPI | ₩61,900 | +0.98% | ₩716M | ₩854B | 6.34% |
Proteina468530 · KOSDAQ | ₩51,500 | +5.21% | ₩10B | ₩572B | 3.78% |
Samyang Holdings000070 · KOSPI | ₩52,400 | +0.77% | ₩490M | ₩407B | 2.68% |
IL Dong Pharmaceutical249420 · KOSPI | ₩12,790 | +1.11% | ₩1.2B | ₩405B | 2.30% |
Dong-A ST170900 · KOSPI | ₩34,900 | 0.00% | ₩337M | ₩340B | 4.78% |
Inventage Lab389470 · KOSDAQ | ₩23,950 | +5.04% | ₩1.8B | ₩319B | 0.31% |
Prestige BioPharma950210 · KOSPI | ₩4,220 | −16.44% | ₩3B | ₩254B | 0.15% |
Huons243070 · KOSDAQ | ₩17,330 | +0.81% | ₩286M | ₩208B | 0.71% |
Binex053030 · KOSDAQ | ₩6,100 | +0.49% | ₩379M | ₩199B | 2.17% |
BNC Korea256840 · KOSDAQ | ₩2,485 | +0.40% | ₩1B | ₩170B | — |
Kolon Life Science102940 · KOSDAQ | ₩12,940 | +1.41% | ₩608M | ₩169B | 0.50% |
Prestige Biologics334970 · KOSDAQ | ₩1,166 | −5.28% | ₩703M | ₩91B | — |
GL Pharm Tech204840 · KOSDAQ | ₩3,575 | −0.14% | ₩81M | ₩55B | — |
Aprogen Biologics003060 · KOSPI | ₩1,394 | +0.50% | ₩114M | ₩42B | 0.08% |
SeouLin Bioscience038070 · KOSDAQ | ₩3,670 | +1.24% | ₩33M | ₩34B | — |
BioInfra Life Science266470 · KONEX | ₩99 | +4.21% | ₩180,195 | ₩2.8B | — |
Source: KRX statistical information